Abstract
Extension of SIR type models has been reported in a number of publications in mathematics community. But little is done on validation of these models to fit adequately with multiple clinical data of an infectious disease. In this paper, we introduce SEIR-PAD model to assess susceptible, exposed, infected, recovered, super-spreader, asymptomatic infected, and deceased populations. SEIR-PAD model consists of 7-set of ordinary differential equations with 8 unknown coefficients which are solved numerically in MATLAB using an optimization algorithm. Four set of COVID-19 clinical data consist of cumulative populations of infected, deceased, recovered, and susceptible are used from start of the outbreak until 23rd June 2020 to fit with SEIR-PAD model results. Results for trends of COVID-19 in GCC countries indicate that the disease may be terminated after 200 to 300 days from start of the outbreak depends on current measures and policies. SEIR-PAD model provides a robust and strong tool to predict trends of COVID-19 for better management and/or foreseeing effects of certain enforcing laws by governments, health organizations or policy makers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no fund
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Obuda University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
